New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
16:24 EDTDOLE, ZIP, UNH, X, JNJ, HPQ, SKUL, CAR, MRKOn The Fly: Closing Wrap
Stocks on Wall Street were significantly higher after U.S. lawmakers agreed on a deal to prevent falling off the fiscal cliff late last night. Several issues, including the debt ceiling, were pushed off by the agreement, but the stop-gap measure provided investors with enough temporary stability to send the market sharply higher at the open. The averages did not move far from their early levels and closed at the highs of the session... ECONOMIC EVENTS: In the U.S., Markit's final reading for December's purchasing managers' index came in at 54.0, which was up from 52.8 a month ago and beat expectations for a downward revision to 53.6. The ISM's December manufacturing PMI had a reading of 50.7, versus the expected 50.5, while the prices paid index came in at 55.5, versus the expected 50.8. A separate report showed construction spending fell 0.3% in November, versus an expected increase of 0.6%... COMPANY NEWS: Every member of the Dow Jones Industrial Average gained on the session, though UnitedHealth (UNH) rose only 30c, or 0.55%, to $54.54 and fellow healthcare companies Merck (MRK) and Johnson & Johnson (JNJ) were the average's other laggards. Shares of Hewlett-Packard (HPQ) lead the index, gaining 77c, or 5.4%, to $15.02... MAJOR MOVERS: Among the notable gainers was Zipcar (ZIP), which rose $3.94, or 47.82%, to $12.18 following its agreement to be acquired for $12.25 per share in cash by Avis Budget (CAR). Avis shares also gained 95c, or 4.79%, to $20.77. Also higher were shares of U.S. Steel (X), up $2.04, or 8.55%, to $25.89 after an upgrade to Outperform and a price target raise to $30 from $20 per share at Credit Suisse. Among noteworthy losers were shares of Dole Food (DOLE), which fell $1.54, or 13.43%, to $9.93 after the company said its fresh fruit business continues to experience declining earnings. Also lower was Skullcandy (SKUL), down 99c, or 12.71%, to $6.80 after Jefferies downgraded the stock two notches, to Underperform from Buy... INDICES: The Dow was up 308.41, or 2.35%, to 13,412.55; the Nasdaq was up 92.75, or 3.07%, to 3,112.26; and the S&P 500 was up 36.23, or 2.54%, to 1,462.42.
News For HPQ;UNH;MRK;JNJ;ZIP;CAR;X;DOLE;SKUL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 14, 2015
06:15 EDTHPQHP Q2 sales weakness largely expected, says Citigroup
Citigroup believes HP's Q2 revenue on May 21 could miss the consensus expectation of $25.8B due to PC weakness and currency pressure. Citi thinks sales weakness is largely expected, however. The firm says HP shares "will start to work again" as management will likely address and quantify the additional costs of operating as two separate companies. Uncertainty around the size of the dis-synergy costs has been a key factor behind the stock's recent underperformance, Citi believes. It keeps a Buy rating on HP with a $41 price target.
May 13, 2015
18:33 EDTMRKMerck to present new Keytruda data on 10 types of cancer at 2015 ASCO meeting
Subscribe for More Information
17:50 EDTJNJPharmacyclics to showcase new 'promising' Imbruvica data at ASCO
Pharmacyclics announced that ibrutinib, also known as Imbruvica, single-agent and combination data will be featured in seven oral and poster sessions at the 51st American Society of Clinical Oncology, ASCO, Annual Meeting being held May 29-June 2 in Chicago, IL. According to a statement from ASCO, Imbruvica data will also be included in the official press program during the meeting for the second time in two years. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a Johnson & Johnson (JNJ) subsidiary. Data being presented include, among others, an oral presentation from the Phase III HELIOS study of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia, a poster presentation of ibrutinib in steroid-dependent or refractory chronic graft-versus-host-disease as well as a dose adherence analysis of ibrutinib 420 mg administered to previously treated CLL patients. "We look forward to sharing promising data at this year's ASCO that examines the use of Imbruvica across a broad range of hematologic disease settings from our clinical studies," said Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics.
13:12 EDTMRKSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
12:43 EDTHPQHewlett-Packard volatility elevated into Q2 and outlook
Subscribe for More Information
05:48 EDTXStocks with implied volatility movement; DHR X
Subscribe for More Information
May 12, 2015
13:13 EDTMRKExpert says Norway biosimilar case an 'outlier,' CT Financial News reports
Subscribe for More Information
12:52 EDTXOptions with increasing call volume and implied volatility
Subscribe for More Information
10:14 EDTXU.S. Steel moves higher, levels to watch
Subscribe for More Information
10:10 EDTXU.S. Steel call activity attributed to takeover speculation
Subscribe for More Information
10:04 EDTXRumor: U.S. Steel strength attributed to takeover speculation
Subscribe for More Information
08:08 EDTXNow is the time to buy U.S. Steel, says Morgan Stanley
Subscribe for More Information
06:09 EDTMRKThreshold announces Merck receives FDA Fast Track designation for evofosfamide
Subscribe for More Information
May 11, 2015
17:58 EDTJNJJ&J's Janssen gets complete response letter regarding sNDA for Invega Sustenna
Subscribe for More Information
07:50 EDTHPQHP awarded IT services contract by California WCDS
Subscribe for More Information
07:40 EDTUNHFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:13 EDTUNHUnitedHealth management to meet with UBS
Subscribe for More Information
May 10, 2015
19:25 EDTJNJCourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
14:05 EDTJNJJohnson & Johnson shares may deliver double-digit returns, Barron's says
Subscribe for More Information
13:48 EDTHPQ3D Systems stock may tumble another 30%, Barron's says
Shares of 3D Systems (DDD) could lose another 30% as the company faces development delays, low demand, and the entry of Hewlett-Packard (HPQ) into the market by 2016, Barron's contends in its "Follow Up" column. Barron's maintains its price forecast of $15. Reference Link
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use